Equities analysts predict that Inogen, Inc (NASDAQ:INGN) will announce $59.17 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Inogen’s earnings, with the lowest sales estimate coming in at $56.92 million and the highest estimate coming in at $60.61 million. Inogen reported sales of $54.57 million during the same quarter last year, which suggests a positive year over year growth rate of 8.4%. The business is scheduled to announce its next earnings report on Thursday, August 3rd.

On average, analysts expect that Inogen will report full year sales of $59.17 million for the current financial year, with estimates ranging from $237.50 million to $240.20 million. For the next fiscal year, analysts anticipate that the company will post sales of $280.08 million per share, with estimates ranging from $277.21 million to $283.88 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Inogen.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, May 9th. The medical technology company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.15. The company had revenue of $52.50 million for the quarter, compared to the consensus estimate of $49.06 million. Inogen had a return on equity of 11.67% and a net margin of 9.32%. The firm’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same period last year, the firm earned $0.12 EPS.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “strong-buy” rating and set a $94.00 price target on the stock in a research note on Monday, May 15th. Needham & Company LLC boosted their price target on shares of Inogen from $96.00 to $108.00 and gave the stock a “strong-buy” rating in a research note on Friday, June 9th. Stifel Nicolaus boosted their price target on shares of Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a research note on Wednesday, May 10th. TheStreet upgraded shares of Inogen from a “c” rating to a “b-” rating in a research note on Tuesday, February 28th. Finally, J P Morgan Chase & Co upped their target price on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $91.60.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/06/28/inogen-inc-ingn-expected-to-post-quarterly-sales-of-59-17-million.html.

Shares of Inogen (NASDAQ INGN) traded up 2.0696% during midday trading on Wednesday, reaching $93.6999. The company’s stock had a trading volume of 52,843 shares. Inogen has a 52 week low of $44.26 and a 52 week high of $95.43. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of 83.8103 and a beta of 1.04. The company has a 50 day moving average of $87.37 and a 200-day moving average of $74.82.

In other Inogen news, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $75.28, for a total transaction of $188,200.00. Following the transaction, the executive vice president now directly owns 4,064 shares in the company, valued at $305,937.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ray Benjamin M. Anderson sold 4,445 shares of the company’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $81.05, for a total transaction of $360,267.25. Following the transaction, the director now owns 4,445 shares in the company, valued at $360,267.25. The disclosure for this sale can be found here. Insiders have sold 83,848 shares of company stock worth $7,283,201 over the last 90 days. 5.31% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new stake in Inogen during the first quarter valued at approximately $109,000. Victory Capital Management Inc. raised its stake in Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock valued at $134,000 after buying an additional 459 shares in the last quarter. State of Alaska Department of Revenue raised its stake in Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock valued at $138,000 after buying an additional 70 shares in the last quarter. Jane Street Group LLC acquired a new stake in Inogen during the first quarter valued at approximately $203,000. Finally, Guggenheim Capital LLC acquired a new stake in Inogen during the fourth quarter valued at approximately $211,000.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.